DK0610179T3 - Målspecifikke antistof-superantigenkonjugater og fremstilling deraf - Google Patents

Målspecifikke antistof-superantigenkonjugater og fremstilling deraf

Info

Publication number
DK0610179T3
DK0610179T3 DK91914023.6T DK91914023T DK0610179T3 DK 0610179 T3 DK0610179 T3 DK 0610179T3 DK 91914023 T DK91914023 T DK 91914023T DK 0610179 T3 DK0610179 T3 DK 0610179T3
Authority
DK
Denmark
Prior art keywords
conjugate
target
cells
lysis
preparation
Prior art date
Application number
DK91914023.6T
Other languages
Danish (da)
English (en)
Inventor
Peter Lando
Eva Akerblom
Terje Kalland
Gunnar Hedlund
Mikael Dohlsten
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002479A external-priority patent/SE9002479D0/xx
Priority claimed from SE9002484A external-priority patent/SE9002484L/xx
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of DK0610179T3 publication Critical patent/DK0610179T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK91914023.6T 1990-07-20 1991-07-16 Målspecifikke antistof-superantigenkonjugater og fremstilling deraf DK0610179T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002479A SE9002479D0 (sv) 1990-07-20 1990-07-20 Antibody conjugates
SE9002484A SE9002484L (sv) 1990-07-20 1990-07-20 Nya substituerade polyetrar

Publications (1)

Publication Number Publication Date
DK0610179T3 true DK0610179T3 (da) 1997-03-24

Family

ID=26660818

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91914023.6T DK0610179T3 (da) 1990-07-20 1991-07-16 Målspecifikke antistof-superantigenkonjugater og fremstilling deraf

Country Status (16)

Country Link
EP (1) EP0610179B1 (fr)
JP (1) JP3334130B2 (fr)
KR (1) KR100189024B1 (fr)
AT (1) ATE144145T1 (fr)
AU (1) AU656906B2 (fr)
CA (1) CA2087164C (fr)
DE (1) DE69122777T2 (fr)
DK (1) DK0610179T3 (fr)
ES (1) ES2094231T3 (fr)
GR (1) GR3022202T3 (fr)
HK (1) HK1007955A1 (fr)
HU (1) HU218603B (fr)
LV (1) LV10201B (fr)
NO (1) NO312816B1 (fr)
RU (1) RU2125889C1 (fr)
WO (1) WO1992001470A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
SE9102074D0 (sv) * 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
GB9114399D0 (en) * 1991-07-03 1991-08-21 Ici Plc Conjugates
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0659438A1 (fr) * 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugués d'un antigène peptidique pour cellules-T et d'un groupé liant aux cellules, et leur utilisation en thérapie
GB9326574D0 (en) * 1993-12-31 1994-03-02 King S College London Dry power inhalers
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
ES2299177T3 (es) 1995-05-10 2008-05-16 Kyowa Hakko Kogyo Co., Ltd. Conjugados de citotoxinas que contienen dipeptidos.
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
JP2002520297A (ja) 1998-07-13 2002-07-09 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム アミノリン脂質に結合する治療結合体を用いる癌処置方法
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5004692A (en) * 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
EP0334300A1 (fr) * 1988-03-21 1989-09-27 Neorx Corporation Utilisation d'anticorps monoclonaux et de conjugués de ceux-ci comme signaux pour diriger des cellules effecteurs sensibilisées sur des lieux tumoraux
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体

Also Published As

Publication number Publication date
DE69122777T2 (de) 1997-04-10
NO930174L (no) 1993-01-19
AU8294191A (en) 1992-02-18
JP3334130B2 (ja) 2002-10-15
GR3022202T3 (en) 1997-03-31
ATE144145T1 (de) 1996-11-15
KR100189024B1 (ko) 1999-06-01
LV10201A (lv) 1994-10-20
WO1992001470A1 (fr) 1992-02-06
CA2087164A1 (fr) 1992-01-21
HU9300148D0 (en) 1993-04-28
RU2125889C1 (ru) 1999-02-10
HK1007955A1 (en) 1999-04-30
HU218603B (hu) 2000-10-28
AU656906B2 (en) 1995-02-23
NO312816B1 (no) 2002-07-08
ES2094231T3 (es) 1997-01-16
HUT67502A (en) 1995-04-28
JPH05508856A (ja) 1993-12-09
NO930174D0 (no) 1993-01-19
EP0610179B1 (fr) 1996-10-16
LV10201B (en) 1995-08-20
EP0610179A1 (fr) 1994-08-17
CA2087164C (fr) 2002-11-26
DE69122777D1 (de) 1996-11-21

Similar Documents

Publication Publication Date Title
DK0610179T3 (da) Målspecifikke antistof-superantigenkonjugater og fremstilling deraf
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
NO924088D0 (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse derav
EP0911036A3 (fr) Structure immunogene à double vecteur
CA2078118A1 (fr) Analogues de cc-1065
DK0693132T3 (da) Rapamycinassay
RU93004918A (ru) Новые конъюгаты антитело-суперантиген, способ их получения, способ лизирования клетки-мишени, способ лечения и использование конъюгатов для получения фармкомпозиции
ATE137242T1 (de) Kovalente-ther lipidnukleosid-konjugate
EA199901016A1 (ru) 9-оксим-производные эритромицина
CA2434009A1 (fr) Conjugues de composes de macrolide specifiques de cellules immunitaires avec des composes anti-inflammatoires, permettant un ciblage cellulaire ameliore d'une therapie anti-inflammatoire
CA2067244A1 (fr) Anticorps monoclonal specifique pour recepteur d'iga
NO920942D0 (no) Konjugert vaksine for gruppe b streptococcus
AU7556487A (en) Immunotoxins, process for their preparation and pharmaceutical compositions in which they are present
WO2005108430A3 (fr) Elements de liaison specifique
AU6628386A (en) Ricin-antibody conjugates
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
DK45080A (da) Fremgangsmaade til fremstilling af anthracyclinglycosider
CA2141025A1 (fr) Anticorps monoclonal dirige contre les mucoproteines
TH11834EX (th) แอนติบอดีสังยุค
TH13782EX (th) คู่สังยุคชนิดใหม่สำหรับการให้กรดนิวคลีอิคเข้าสู่เซลล์ยูคารีโอทชั้นสูง
AU7664194A (en) Use of antibodies against beta -2 microglobulin-free, class i hla molecules to provide hiv diagnostic tests as well as compositions having a protective action against hiv infections